Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. (11th January 2020)

• Record Type: Journal Article
• Authors: Ryu, Jai Min; Nam, Seok Jin; Kim, Seok Won; Lee, Jeong Eon; Chae, Byung Joo; Lee, Se Kyung; Yu, Jonghan
• Is Part Of: Japanese journal of clinical oncology. Volume 50:Number 2(2020)
• Page Start: 104
• Page End: 113
• Publication Date: 2020-01-11
• Subjects: breast neoplasm -- BRCA mutation -- hereditary breast and ovarian cancer syndrome; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyz147
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Objective: Demands for genetic counseling with BRCA1/2 examination have markedly increased. Accordingly, the incidence of uninformative results on BRCA1/2 mutation status has also increased. Because most patients examined for BRCA1/2 mutation have a high risk of hereditary breast and/or ovarian cancer, many patients suffer psychological distress even when the BRCA1/2 result is negative. We compared oncological outcomes between BRCA1/2-negative breast cancer with high risk of hereditary breast and/or ovarian cancer and sporadic breast cancer without risk of hereditary breast and/or ovarian cancer. Methods: The criteria for high risk for hereditary breast and/or ovarian cancer were defined as family history of breast and/or ovarian cancer in first- or second-degree relative, early onset breast cancer at <35 years old and bilateral breast cancer. Patients were matched maximally 1:3 into those who identified as negative for BRCA1/2 mutation with risk of hereditary breast and/or ovarian cancer (study group) and those who were not examined for BRCA1/2 mutation without risk for hereditary breast and/or ovarian cancer (control group). Matched variables were pathologic stage, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 status. Results: All matching variables were successfully matched. Median follow-up duration was 57.8 months. There was no significant difference between the groups in disease-free survival (log-rank P = 0.197); however, the study group showed significantly better overall survival and breast cancer-specific survival (both P < 0.0001). We conducted subgroup analysis in the middle-aged group (36–54) and showed no significant difference for disease-free survival ( P = 0.072) but significantly better overall survival and breast cancer-specific survival in the study group ( P = 0.002 and P < 0.0001). Conclusions: BRCA1/2-negative breast cancer patients who had hereditary breast and/or ovarian cancer risk factors showed similar disease-free survival and better overall survival and breast cancer-specific survival compared with those with sporadic breast cancer without hereditary breast and/or ovarian cancer risk factors. Abstract : Compared the prognosis of BRCA1/2 (−) BC with high risk of hereditary breast and/or ovarian cancer and sporadic BC without risk of hereditary breast and/or ovarian cancer, BRCA1/2 (−) showed similar disease-free survival and better overall survival and breast cancer–specific survival.